September 3, 2019 / 5:30 AM / 19 days ago

BRIEF-Polpharma Biologics Announces Global Commercialization Deal For Biosimilar Natalizumab

Sept 3 (Reuters) - Polpharma Biologics:

* POLPHARMA BIOLOGICS ANNOUNCES GLOBAL COMMERCIALIZATION DEAL FOR BIOSIMILAR NATALIZUMAB

* HAS ENTERED A GLOBAL COMMERCIALIZATION AGREEMENT WITH SANDOZ AG FOR A NATALIZUMAB BIOSIMILAR

* MEDICINE IS CURRENTLY IN PHASE III CLINICAL DEVELOPMENT FOR TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS

* UNDER AGREEMENT, CO WILL BE RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING, SUPPLY OF COLLABORATION BIOSIMILAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below